Common platinum agents, such as cisplatin, target highly proliferative cancer cells and are frequently used in combination with other agents, including anti-epidermal growth factor receptor (EGFR) agents, cetuximab, and anti-programmed death protein 1 (PD-1) drugs; the response rates of pembrolizumab as indicated by objective indicators were found to be 36% and 43%, respectively [4,5]. The gene discussed is EGFR; the disease is cancer.